Positive UK PIP Decision & PDCO opinion ratification by EMA
Filed with ASX · · 2 pages · English
Percheron Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Percheron Therapeutics
- ATL1102 Toxicology Protocol submitted to US FDA
- Investor Presentation
- Positive PDCO opinion and A$20m Placement
- Positive feedback received on Paediatric Investigation Plan
- New data supports ATL1102s broader clinical potential
Later from Percheron Therapeutics
- Annual General Meeting Presentation
- Entitlement Offer Results
- Quarterly Report and Appendix 4C
- Dosing commenced in MCRI collaboration animal study
- Long COVID-19 strategic collaboration with US Experts
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics